Immune disorders & Inflammation
Over the last decades, worldwide epidemiological data have shown evidence of a steady rise in autoimmune and inflammatory diseases. Among them, one can list gastrointestinal (e.g. IBD), dermatological (e.g. psoriasis), respiratory (e.g. asthma) and metabolic diseases (e.g. obesity and T2DM).
The NHP model is a clinically relevant model to assess drug’s efficacy in these therapeutic indications as it displays great similarities with the human immune system, both at the innate and adaptive level. This in vivo model is thus highly relevant from a clinical and immunological point of view, enabling the exploration of the mechanisms involved and the assessment of innovative treatments.
Cynbiose has developed an in-depth understanding in immunology and inflammatory processes in the NHP. This has led to the development of predictive Proof-of-Concept models and novel clinically relevant measurements.
Moreover, Cynbiose has built a partnership with Hawkcell specialized in magnetic resonance imaging (MRI) for preclinical research studies. The company operates 1.5T and 3T MRI systems, design of customized sensors and holds IT development capabilities. MRI is a powerful tool for in vivo quantitative analysis of multiple characteristics of living tissues such as inflammation, vascular network, MRI-guided surgery, … for drug efficacy or medical device biocompatibility tests.
- Imiquimod-induced psoriasis model
- Skin allograft survival model
- Experimental Autoimmune Encephalomyelitis (EAE) model
- On-demand preclinical models: contact us to discuss your needs
- Pharmacokinetics
- Pharmacodynamics
- Early toxicology studies
- Delayed-Type Hypersensitivity (DTH) model
Imiquimod-induced psoriasis model
This non-human primate (NHP) model induces chronic skin inflammation and plaques with lesions markedly similar to those observed in human patients.
This is a simple and fast in vivo model to evaluate the efficacy of your drug.
Model
- Species: Cynomolgus macaque (Macaca fascicularis)
- Topical application of imiquimod (IMQ) cream triggering a dermal autoimmune response
- Validation of the model : both clinical and histopathological validation
Type of test item
- Immunotherapies
- Immunomodulators
Efficacy readouts
- Scoring of skin erythema, skin inflammation and other clinical signs lesions observed as in human
- Clinical pathology
- Immunomonitoring
- Skin biopsies, tissue collection
- Histopathology
- Immunohistochemistry
- On-demand and customized readouts
Skin allograft survival model
This model compares the transplantation of skin allograft and autograft between two animals to evaluate novel immunosuppressive treatments.
A simple and fast in vivo model to evaluate the efficacy of your drug.
Model
- Species: Cynomolgus macaque (Macaca fascicularis)
- Validation of the model :
- Clinical and histopathological validation
- Validated with reference immunosuppressive drug (Thymoglobulin)
Type of test item
- Immunotherapies
- Immunomodulators
Efficacy read-outs
- Scoring of skin graft, skin inflammation and other clinical signs lesions observed as in human
- Clinical pathology
- Immunomonitoring
- Skin biopsies, tissue collection
- Histopathology
- Immunohistochemistry
- On-demand and customized readouts
Experimental Autoimmune Encephalomyelitis (EAE) model
This model induces an auto-immune reaction of the animal against its own myelin sheet, thus reproducing the phenotype of several auto-immune demyelinating diseases (Serguera et al., 2019).
The Experimental Autoimmune Encephalomyelitis (EAE) NHP model has indeed been shown to mimic several aspects of the immune response, neuroinflammation and behavioral phenotype observed in the multiple sclerosis (Stimmer et al., 2018 & Stimmer et al, 2021).
This model is not commercially available at the moment.
Model
- Species: Cynomolgus macaque (Macaca fascicularis)
- Pharmacologically-induced autoimmune reaction
Type of test item
- Neuroprotective or immunosuppressive therapeutic strategies in a neurological auto-immune disease
- Novel imaging methods targeting the myelin sheet
Efficacy read-outs
- MRI, PET-MRI Imaging
- Daily neurological evaluation (proprietary scoring grid)
- Clinical pathology
- Immunomonitoring
- On-demand and customized readouts
Scientific publications
- Recombinant myelin oligodendrocyte glycoprotein (MOG) quality modifies evolution of EAE in macaques.
Stimmer L, Confais J, Jong A, Verth J, Fovet CM, Horellou P, Massonneau J, Perrin A, Miotello G, Avazeri E, Hart B, Deiva K, Le Grand R, Armengaud J, Bajramovic J, Contamin H, and Serguera C.
Laboratory Investigation, August 2021.
https://doi.org/10.1038/s41374-021-00646-x
Reference compounds
- Experimental tetramer
Scientific partners
- CERMEP – Imagerie du Vivant, Lyon, France
- CREATIS, CNRS UMR-5220, INSERM U1206, Université Lyon 1, France
On-demand preclinical models: contact us to discuss your needs
The selection of the appropriate animal model to evaluate the efficacy of your drug candidates is critical to your preclinical research success.
Cynbiose is committed to providing you with clinically relevant animal models, outstanding surgical and technical capabilities as well as high-quality data.
For more information, visit our specific page dedicated to customized efficacy models.
We’d be pleased to discuss your needs and projects. Feel free to contact our teams.
Pharmacokinetics
Pharmacokinetics
- Circulating drug kinetics following most routes of administration (more information)
- Cutting-edge expertise for in vivo central pharmacokinetics
- Blood sampling
- Cerebrospinal fluid (CSF) drug levels
- Brain microdialysis to monitor neurotransmitters, drugs or metabolites in the extracellular cerebral fluid.
Discover our proprietary platform Kine C3
Clinical follow-up and Bioanalysis
- Daily clinical monitoring for the early detection of adverse effects
- Monitoring of physiological parameters and other biomarkers of interest
- Bioanalysis (more information)
Pharmacodynamics
More information here.
Early toxicology studies
Type of studies
- Single and repeated doses, dose escalating studies
- Immunosafety, immunogenicity
- Pulmonary tox and respiratory function
- Dose Range Finding (DRF)
- Maximum Tolerated Dose (MTD)
Type of test item
- Immunotherapies
- Antibodies, ADC, …
- Cell therapies, gene therapies, oncolytic virus
- Oligonucleotides, antisense oligonucleotides
- Therapeutic vaccines such as DNA vaccines, RNA vaccines
- Recombinant proteins, recombinant enzymes
- Peptides
- Oncolytic viruses (BSL2 biocontainment, GMO C2)
- Small molecules, ….
non-exhaustive list
Delayed-Type Hypersensitivity (DTH) model
Delayed-type hypersensitivity (DTH) is a low invasive model based on the induction of local cellular immune responses.
This NHP model is reliable for the preclinical evaluation of cell-mediated immunity of biological drugs and non clinical immunotoxicity evaluation.
Model
- Species: Cynomolgus macaque (Macaca fascicularis)
- Model induced by KLH, Tetanus-based vaccine (TTx), BCG
Type of test item
- Immunosuppressive agents
- Immunomodulatory drugs
- Vaccines / adjuvants
Efficacy read-outs
- Clinical reactions at the injection sites (proprietary scoring grid)
- Clinical pathology
- Cutaneous reaction : morphological readouts, histopathology, immunohistochemistry
- Immunomonitoring
- On-demand and customized readouts
Scientific publications
- Développement préclinique des immunothérapies : apport des modèles PNH. Verset M, Mosca M, Panzuti P, Contamin H, Pin D. STAL. 2018, 46(2): 12-16.
- Preclinical development of immunotherapies for infectious diseases: relevance of the Non-Human Primate. Verset M, Contamin H. I4ID congress, 2017, 11-12 Dec. 2017, Lyon.
- Développement préclinique des immunothérapies : apport des modèles PNH. Verset M et al. 43ème colloque AFSTAL, 7-9 Juin 2017, Lyon.
